25 A retrospective analysis of patients with advanced EGFR mutated lung cancer treated with either first line erlotinib or gefitinib

Kiruthikah Thillai(Guy's and St Thomas' NHS Foundation Trust), Rohit Lal, Eleni Karapanagiotou(King's College London), James Spicer(King's College London), Aspasia Soultati, Ana Montes(Guy's and St Thomas' NHS Foundation Trust)

Lung Cancer

January 1, 2014

10.1016/s0169-5002(14)70026-1

Cited by 0

Related Papers

Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal

|Cell|2018|883

Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal

|Cell|2018|680

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

|The Lancet Oncology|2021|614

Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal

|Cell|2018|565

Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial

|The Lancet Oncology|2019|228